Nuvig Therapeutics
About Nuvig Therapeutics
Nuvig Therapeutics develops second-generation immunomodulators that utilize endogenous regulatory mechanisms to restore immune homeostasis in patients with chronic inflammatory and autoimmune diseases. Their therapies aim to treat underlying inflammation without compromising overall immune function, improving treatment options for affected individuals.
```xml <problem> Current treatments for chronic inflammatory and autoimmune diseases often suppress the entire immune system, leading to increased susceptibility to infections and other complications. There is a need for therapies that can selectively modulate the immune response to address the underlying inflammation without compromising overall immune function. </problem> <solution> Nuvig Therapeutics is developing second-generation immunomodulators designed to restore immune homeostasis in patients with chronic inflammatory and autoimmune diseases. Their approach leverages endogenous regulatory mechanisms to resolve autoimmune dysregulation, offering a more targeted treatment compared to broad immunosuppressants. The company's therapies aim to treat the underlying inflammatory disease without compromising overall immune function, potentially improving treatment outcomes and reducing side effects for affected individuals. Nuvig's lead candidate, NVG-2089, is progressing to Phase 2 clinical development. </solution> <features> - Utilizes endogenous regulatory mechanisms to rebalance the immune system. - Designed to selectively modulate the immune response, avoiding broad immunosuppression. - Aims to resolve autoimmune dysregulation at its source. - NVG-2089, a next-generation immunomodulator, is in Phase 2 clinical trials for chronic inflammatory demyelinating polyneuropathy (CIDP). </features> <target_audience> The primary target audience includes patients suffering from chronic inflammatory and autoimmune diseases, as well as physicians specializing in rheumatology, immunology, and related fields. </target_audience> ```
What does Nuvig Therapeutics do?
Nuvig Therapeutics develops second-generation immunomodulators that utilize endogenous regulatory mechanisms to restore immune homeostasis in patients with chronic inflammatory and autoimmune diseases. Their therapies aim to treat underlying inflammation without compromising overall immune function, improving treatment options for affected individuals.
Where is Nuvig Therapeutics located?
Nuvig Therapeutics is based in Palo Alto, United States.
When was Nuvig Therapeutics founded?
Nuvig Therapeutics was founded in 2023.
How much funding has Nuvig Therapeutics raised?
Nuvig Therapeutics has raised 208000000.
Who founded Nuvig Therapeutics?
Nuvig Therapeutics was founded by Ciara Kennedy and Sheldon Koenig.
- Ciara Kennedy - CEO
- Sheldon Koenig - Founder
- Location
- Palo Alto, United States
- Founded
- 2023
- Funding
- 208000000
- Employees
- 24 employees
- Major Investors
- Sanofi Ventures, Norwest Venture Partners